美股異動 | Moderna盤前漲2% 奧密克戎二價增強劑候選藥物二階段研究首名參與者接種完畢
格隆匯3月15日丨Moderna(MRNA.US)盤前漲2.21%,報153.38美元,總市值618億美元。消息面上,公司近日宣佈奧密克戎的二價增強劑候選藥物(mRNA1-1273.214)的第二階段研究的第一名參與者已經接種完畢,該候選藥物將Moderna的奧密克戎專用加強劑候選藥物(mRNA1-1273.529)和Moderna新冠疫苗(MRNA1273)相結合。CEOStéphane Bancel稱,概定製疫苗將針對在新的新冠變種,並致力於生成數據並與公共衞生當局共享數據,當局正在為秋季強化季節做準備。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.